Comparison of Tc-99m DTPA Aerosol Ventilation Studies with Pulmonary Function Testing in Cystic Fibrosis

1993 ◽  
Vol 18 (1) ◽  
pp. 15-18 ◽  
Author(s):  
C C KUNI ◽  
J R BUDD ◽  
W E REGELMANN ◽  
R P DUCRET ◽  
R J BOUDREAU
2017 ◽  
Vol 158 (2) ◽  
pp. 381-385 ◽  
Author(s):  
Sabrina Khalfoun ◽  
Dmitry Tumin ◽  
Maroun Ghossein ◽  
Meredith Lind ◽  
Don Hayes ◽  
...  

Objectives Cystic fibrosis (CF) is characterized by infection and inflammation of the sinorespiratory tract. Functional endoscopic sinus surgery (FESS) is an option for patients with severe sinusitis. We sought to evaluate pulmonary function testing after FESS in pediatric and adult patients with CF. Study Design Retrospective chart review using data from all patients with CF who underwent FESS from January 2009 to July 2014. Setting Patients were from a single institution. Subjects and Methods Data were extracted for 181 patients and 320 surgeries. Lung function data, including the forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC, were retrieved within 1 year before and after surgery. Mixed-effects regression was used to compare FEV1 trajectories before and after surgery. The effect of surgery was stratified by presurgery FEV1 to compare patients with mild/no lung disease (FEV1 >80%) and moderate/severe lung disease (FEV1 <80%). Results Of the 181 patients reviewed, 131 with primary FESS had FEV1 data. Presurgery average age was 16 years (95% confidence interval [CI], 14.27-17.73), and FEV1 mean was 85% (95% CI, 81.02-88.98). There were 88 patients with FEV1 >80% and 43 patients with FEV1 <80%. For the entire cohort, lung function did not change related to FESS. Among patients with FEV1 <80%, FEV1 declined presurgery by 3.5% per year (95% CI, −6.1% to −0.8%; P = .010), which halted after surgery with these patients, then showing no subsequent change in FEV1 (95% CI, 0.9%-3.7%; P = .240). No benefit was identified for patients with FEV1 >80%. Conclusion Pulmonary function testing improved in patients with moderate/severe lung disease 1 year following FESS. This suggests FESS may benefit pulmonary outcomes.


CHEST Journal ◽  
2016 ◽  
Vol 150 (4) ◽  
pp. 1130A
Author(s):  
Sabrina Khalfoun ◽  
Dmitry Tumin ◽  
Meredith Lind ◽  
Shahid Sheikh ◽  
Maroun Ghossein ◽  
...  

2020 ◽  
Vol 55 (5) ◽  
pp. 1139-1146
Author(s):  
Kelsey Nusbaum ◽  
Stephanie S. Filigno ◽  
Julie Feldstein ◽  
Elizabeth Hente ◽  
Elizabeth Koch ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document